Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

drug sales

- PMLiVE

Moderna and Immatics announce oncology collaboration worth over $1.7bn

The agreement will focus on the development of bispecifics, cell therapies and cancer vaccines

- PMLiVE

IO Biotech announces new data supporting its therapeutic cancer vaccine

The vaccine showed promise when used in combination with Merck & Co’s Keytruda

- PMLiVE

NIHR awards £2.3m for AI study to improve radiotherapy for lung cancer

The AI tool is expected to help doctors plan each patient’s radiotherapy treatment

- PMLiVE

AstraZeneca’s rare disease unit partners with Verge Genomics in deal worth over $840m

Both will identify drug targets for neurodegenerative and neuromuscular diseases

- PMLiVE

ICR study supports use of new radioactive treatment for advanced prostate cancer

Experts are calling for NICE to assess if the treatment should be made available on the NHS

- PMLiVE

Seagen and Nurix announce oncology partnership worth over $3.4bn

The collaboration will focus on advancing a new class of medicines for use in cancer

- PMLiVE

AstraZeneca shares positive phase 3 results for Tagrisso combination in lung cancer

An estimated 2.2 million people worldwide are diagnosed with lung cancer each year

- PMLiVE

ICR study finds way to determine efficacy of experimental breast cancer drugs

The findings could speed up the development of targeted therapies for breast cancer

- PMLiVE

New screening model shown to predict ten year breast cancer mortality risk

The risk-based screening model works to identify those at the highest risk of cancer

- PMLiVE

Merck receives EC approval for Keytruda combination in gastric cancer

Over one million new cases of gastric cancer were diagnosed globally in 2020

- PMLiVE

NHS England to offer world-first seven-minute cancer treatment injection

Subcutaneous administration of Roche’s Tecentriq could cut treatment time by up to 75%

- PMLiVE

AstraZeneca latest to sue US government over Medicare drug price negotiation plan

The programme already faces court challenges from drugmakers and industry groups

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links